8-K: Cingulate Inc. Announces Positive Second Quarter Results and Progress Towards CTx-1301 NDA Submission

Cingulate Inc. reports positive progress in the development of CTx-1301, including FDA clearance to file for marketing approval, and a $1.6 million capital raise through a warrant inducement.

Summary

• Cingulate Inc. announced its financial results for the second quarter of 2024, highlighting progress in the development of CTx-1301 for ADHD treatment.
• The company received FDA clearance to file for marketing approval of CTx-1301, targeting a New Drug Application (NDA) submission in the first half of 2025.
• Cingulate completed the manufacturing of twelve registration batches for CTx-1301, a requirement for NDA submission.
• A payer study indicated that CTx-1301 is considered a valuable ADHD treatment and is likely to gain coverage.
• The company raised $1.6 million through a warrant inducement in late June, which closed on July 1, 2024.
• Cingulate received an exception from Nasdaq to demonstrate compliance with the $1.00 minimum bid price requirement, subject to a reverse stock split and maintaining a minimum bid price of $1.00 for ten consecutive trading sessions.
• A one-for-twelve reverse stock split was completed on August 9, 2024.
• As of June 30, 2024, Cingulate had $0.4 million in cash, which increased to $2 million after the warrant inducement.
• Total liabilities decreased to $1.9 million as of June 30, 2024, from $8.3 million at the end of 2023.
• Total stockholders' equity increased to $3.1 million as of June 30, 2024, from a negative $6.9 million at the end of 2023.
• R&D expenses decreased to $1.9 million for the quarter, down from $4.5 million in the same period of 2023.
• Net loss for the quarter was $3.2 million, compared to $6.6 million in the same period of 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in drug development and cost management, although the low cash position and need for a reverse stock split temper the overall sentiment.

Positives

• FDA clearance to file for marketing approval of CTx-1301 is a significant milestone.
• Completion of registration batches for CTx-1301 is a key step towards NDA submission.
• The payer study suggests strong market potential for CTx-1301.
• The $1.6 million capital raise provides additional funding.
• The decrease in net loss and R&D expenses indicates improved financial management.
• The increase in stockholders' equity is a positive sign for the company's financial health.

Negatives

• The company had only $0.4 million in cash as of June 30, 2024, which is a low cash position.
• The company is still operating at a loss, with a net loss of $3.2 million for the quarter.
• The company needed to perform a reverse stock split to maintain its Nasdaq listing.

Risks

• The company's low cash position may require additional capital raises.
• There is a risk that the company may not be able to meet the Nasdaq listing requirements.
• The company is still in the development stage and faces regulatory and clinical risks.
• The company's success is heavily dependent on the successful development and commercialization of CTx-1301.

Future Outlook

Cingulate intends to seek opportunities to access additional capital as needed, including non-dilutive capital through potential licensing opportunities and additional equity or debt capital. The company is targeting an NDA submission for CTx-1301 in the first half of 2025.

Management Comments

• Shane Schaffer, Chief Executive Officer of Cingulate, stated that the FDA clearance for filing for marketing approval and completion of the registration batches keeps the company on the path to a targeted NDA submission in the first half of 2025.
• Shane Schaffer also mentioned that they are encouraged by a recent M&A transaction in the ADHD space as they continue to explore licensing opportunities for CTx-1301.

Industry Context

The announcement comes amid increased activity in the ADHD space, as highlighted by a recent M&A transaction. Cingulate's focus on its proprietary Precision Timed Release (PTR) drug delivery platform positions it to potentially capture a share of the market with its next-generation pharmaceutical products.

Comparison to Industry Standards

• While the document does not provide specific comparisons to industry standards, the focus on a novel drug delivery platform (PTR) and the progress towards NDA submission for CTx-1301 are positive indicators.
• The company's ability to secure a payer study indicating strong market potential for CTx-1301 is a positive sign compared to other companies in the space.
• The reduction in R&D and G&A expenses, while a result of cost containment measures, is a positive sign compared to other companies that may be struggling with high operating costs.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split and the potential for future capital raises.
• Employees have experienced salary reductions as part of cost containment measures.
• Patients with ADHD may benefit from the development of CTx-1301.
• Potential licensing partners may be interested in the progress of CTx-1301.

Next Steps

• Cingulate will continue to progress with clinical activities for CTx-1301, including the completion of a Food Effect Study and data analysis of Phase 3 studies.
• The company plans to schedule a pre-NDA meeting and move forward with the submission of the NDA, targeted for the first half of 2025.
• Cingulate will continue to explore additional licensing arrangements for CTx-1301.
• The company will seek opportunities to access additional capital as needed.

Key Dates

Keywords

CTx-1301, ADHD, NDA, FDA, Biopharmaceutical, Warrant Inducement, Reverse Stock Split, Precision Timed Release, PTR, Licensing